共 50 条
- [41] Macrophage Therapy for Acute Liver Injury (MAIL): a study protocol for a phase 1 randomised, open-label, dose-escalation study to evaluate safety, tolerability and activity of allogeneic alternatively activated macrophages in patients with paracetamol-induced acute liver injury in the UKBMJ OPEN, 2024, 14 (12):Humphries, ChristopherAddison, MelisandeAithal, GuruprasadBoyd, JuliaBriody, LesleyCampbell, John D. M.Candela, Maria ElenaClarke, ElliseCoulson, JamesDowning-James, NicholasFontana, Robert JohnGeddes, AilsaGrahamslaw, JuliaGrant, AlisonHeye, AnnaHutchinson, James A.Jones, AshleyMitchell, FionaMoore, JoannaRiddell, AliceRodriguez, AryellyThomas, AngelaTucker, GarryWalker, KimWeir, Christopher J.Woods, RachelZahra, SharonForbes, Stuart J.Dear, James W.
- [42] Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-upBLOOD, 2022, 140 : 7542 - 7544Mi, Jian-QingZhao, WanhongJing, HongmeiFu, WeijunHu, JiandaChen, LijuanZhang, YiwenYao, DanLi, HuiSchecter, Jordan M.Yang, FanSun, HuabinZhuang, Sen HongXu, DaLuo, TracyFan, XiaohuNiu, TingJin, JieChen, Sai-Juan
- [43] Phase 1/2 open-label, multi-center study to assess the safety, tolerability and efficacy of a single dose of PBGM01 delivered into the cisterna magna of subjects with type 1 (early onset) and type 2a (late onset) infantile GM1 gangliosidosisMOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S62 - S63Jarnes, Jeanine R.Day-Salvatore, Debra L.Ficicioglu, CanHastings, CarolineBernard, GenevieveBaruteau, JulienEzgu, FatihGiugliani, RobertoInbar-Feigenberg, MichalWhitley, Chester B.Ni, YanBallard, Victoria L.Haws, Thomas F.Weinstein, David A.
- [44] CHANGE IN FUNCTIONAL ABILITIES IN A PATIENT RECEIVING INVESTIGATIONAL ENZYME REPLACEMENT THERAPY (ERT) FOR MUCOPOLYSACCHARIDOSIS IVA (MPS IVA) IN A PHASE 1/2 MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BMN 110JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S210 - S210Hendriksz, C. J.Decker, C. J.Cheng, S.Hutchinson, J.Takkele, H.
- [45] A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Bessudo, AlbertoCohen, Ezra E. W.Gutierrez, RodolfoJohnson, Daniel H.Rosenberg, AriSukari, AmmarStemmer, Salomon M.Weinberg, Benjamin AdamReuveni, HadasSchickler, MichaelLiang, Bertrand C.
- [46] A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos (t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B-Interim results of the OCTOPUS-1 studyJOURNAL OF HEPATOLOGY, 2024, 80 : S27 - S28Asselah, TarikFung, Scott K.Akhan, SilaChuang, Wan-LongButi, MariaBrunetto, MauriziaAgarwal, KoshDiba, CamelliaJerzorwski, JohnKakuda, ThomasNalpas, CatherineGuinard-Azadian, CarineVerbinnen, ThierryLathouwers, ErkkiDe Creus, AnLenz, OliverBiermer, Michael
- [47] MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumorsCANCER RESEARCH, 2018, 78 (04)Baird, RichardOmlin, AureliusKiemle-Kallee, JoachimFiedler, UlrikeZitt, ChristofFeurstein, DanielHerbst, JoergDawson, Keithvom Baur, ElmarStumpp, MichaelHermann, FrankHarstrick, AndreasSchneeweiss, Andreas
- [48] HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple MyelomaBLOOD, 2020, 136Schade, HenningMadan, SumitMedvedova, EvaNath, RajneeshKnapp, LisaLemon, BryanSun, Liping Laura
- [49] Update: a phase 1/2, open-label study to assess safety, tolerability, biodistribution, radiation dosimetry and PET imaging characteristics of [18F]FPyGal in comparison to in-vitro diagnostic for the assessment of senescence in oncological patients (NCT04536454)CANCER RESEARCH, 2023, 83 (08)LaFougere, ChristianGueckel, BrigitteDittmann, HelmutTrautwein, NilsHinterleitner, MartinaCotton, JonathanReischl, GeraldKienzle, GabrieleSinger, StephanGani, CihanLauer, UlrichPichler, BerndZender, Lars
- [50] A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Becerra, CarlosInfante, Jeffrey R.Garbo, Lawrence E.Gordon, Michael S.Smith, David A.Braiteh, Fadi S.Gandara, David R.Jotte, Robert M.Reckamp, Karen L.Janku, FilipBurris, Howard A.Bellew, Kevin M.Gardner, Olivia S.Liu, LiCox, Donna S.Peddareddigari, Vijay Gopal ReddyBlumenschein, George R.